It suggested that ARID1A might be the regulator in PI3K/Akt, JAK/STAT and NF-κB signaling pathways which are strongly associated with the resistance to EGFR-TKIs in NSCLC patients. This evidence concerns the gene ARID1A and non-small cell lung carcinoma.